Physician profile
Robert Bogle
NPI 1356676845
$1,898.21
in general payments reported to CMS, 2019-2025
22 companies · $693 in 2025
The $693 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.11 · 2023: $197 · 2024: $965 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.10 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $264.02 | 2023-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $167.97 | 2024-2025 | Korlym |
| Pfizer INC. | $126.37 | 2023-2025 | |
| Esperion Therapeutics, INC. | $124.15 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $106.14 | 2025 | Veozah |
| Exact Sciences Corporation | $104.12 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $98.57 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $92.61 | 2024-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.26 | 2023-2024 | Xifaxan |
| Amgen INC. | $68.37 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $59.27 | 2023 | Vraylar, Ubrelvy |
| Bausch Health US, LLC | $58.99 | 2024-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $53.42 | 2024 | Glassia |
| Indivior INC. | $26.50 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $21.38 | 2024 | NP Thyroid 60 |
| Phadia US INC. | $20.00 | 2023 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $19.14 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.83 | 2024 | Ultomiris |
| Grifols USA, LLC | $17.60 | 2025 | Prolastin-C Liquid |
| Alkermes, INC. | $16.61 | 2019 | |
| Fidia Pharma USA INC. | $16.06 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.